Period:
Draw Mode:
| Volume | 41,815 |
|
|||||
| News | - | ||||||
| Day High | 1.13 | Low High |
|||||
| Day Low | 1.06 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CNS Pharmaceuticals Inc | CNSP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.03 | -2.75% | 1.06 | 13:50:20 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.09 | 1.06 | 1.13 | 1.09 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 123 | 41,815 | $ 1.09 | $ 45,737 | - | 0.6105 - 6.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:43:46 | 128 | $ 1.06 | USD |
CNS Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.45M | 4.20M | - | 0 | -15.27M | -3.63 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CNS Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CNSP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.292 | 1.3746 | 1.06 | 1.16 | 29,128 | -0.232 | -17.96% |
| 1 Month | 1.73 | 1.80 | 1.06 | 1.45 | 34,257 | -0.67 | -38.73% |
| 3 Months | 2.17 | 2.66 | 1.06 | 1.85 | 153,406 | -1.11 | -51.15% |
| 6 Months | 1.18 | 4.40 | 0.6105 | 2.29 | 1,941,264 | -0.12 | -10.17% |
| 1 Year | 6.222 | 6.90 | 0.6105 | 2.36 | 994,864 | -5.16 | -82.96% |
| 3 Years | 55.50 | 133.80 | 0.6105 | 31.40 | 866,513 | -54.44 | -98.09% |
| 5 Years | 123.30 | 170.697 | 0.6105 | 33.85 | 705,066 | -122.24 | -99.14% |
CNS Pharmaceuticals Description
| CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. |